Tudor Financial Inc. Has $930,000 Stake in Johnson & Johnson (NYSE:JNJ)

Tudor Financial Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 17.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 6,436 shares of the company’s stock after acquiring an additional 959 shares during the quarter. Tudor Financial Inc.’s holdings in Johnson & Johnson were worth $930,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Priebe Wealth Holdings LLC increased its position in shares of Johnson & Johnson by 39.3% in the fourth quarter. Priebe Wealth Holdings LLC now owns 1,817 shares of the company’s stock valued at $263,000 after acquiring an additional 513 shares during the last quarter. Hoese & Co LLP increased its position in shares of Johnson & Johnson by 15.6% during the 4th quarter. Hoese & Co LLP now owns 2,502 shares of the company’s stock worth $362,000 after purchasing an additional 338 shares during the last quarter. Wealthquest Corp boosted its holdings in shares of Johnson & Johnson by 1.3% in the 4th quarter. Wealthquest Corp now owns 9,277 shares of the company’s stock valued at $1,342,000 after buying an additional 115 shares during the last quarter. Amplius Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 16.1% in the fourth quarter. Amplius Wealth Advisors LLC now owns 5,234 shares of the company’s stock valued at $757,000 after buying an additional 727 shares in the last quarter. Finally, Gemmer Asset Management LLC increased its holdings in Johnson & Johnson by 11.0% during the fourth quarter. Gemmer Asset Management LLC now owns 9,298 shares of the company’s stock worth $1,345,000 after buying an additional 923 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Bank of America dropped their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research note on Friday, January 17th. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $173.27.

Johnson & Johnson Stock Down 1.9 %

Shares of JNJ opened at $145.39 on Thursday. The stock has a market capitalization of $350.04 billion, a PE ratio of 21.04, a P/E/G ratio of 2.50 and a beta of 0.51. The firm’s 50 day moving average is $148.26 and its 200-day moving average is $156.12. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same period last year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.